Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci177413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Shashwat Tripathi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Proto-Oncogene Proteins B-raf, Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Despite being the leading cause of cancer-related childhood mortality, pediatric gliomas have been relatively understudied, and the repurposing of immunotherapies has not been successful. Whole-transcriptome sequencing, single-cell sequencing, and sequential multiplex immunofluorescence were used to identify an immunotherapeutic strategy that could be applied to multiple preclinical glioma models. MAPK-driven pediatric gliomas have a higher IFN signature relative to other molecular subgroups. Single-cell sequencing identified an activated and cytotoxic microglia (MG) population designated MG-Act in BRAF-fused, MAPK-activated pilocytic astrocytoma (PA), but not in high-grade gliomas or normal brain. T cell immunoglobulin and mucin domain 3 (TIM3) was expressed on MG-Act and on the myeloid cells lining the tumor vasculature but not normal brain vasculature. TIM3 expression became upregulated on immune cells in the PA microenvironment, and anti-TIM3 reprogrammed ex vivo immune cells from human PAs to a proinflammatory cytotoxic phenotype. In a genetically engineered murine model of MAPK-driven, low-grade gliomas, anti-TIM3 treatment increased median survival over IgG- and anti–PD-1–treated mice. Single-cell RNA-Seq data during the therapeutic window of anti-TIM3 revealed enrichment of the MG-Act population. The therapeutic activity of anti-TIM3 was abrogated in mice on the CX3CR1 MG–KO background. These data support the use of anti-TIM3 in clinical trials of pediatric low-grade, MAPK-driven gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery.
- Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, and.
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Caris Life Sciences, Phoenix, Arizona, USA.
- Department of Pediatrics, Penn State Cancer Institute, Hershey, Pennsylvania, USA.
- Department of Pathology and Laboratory Medicine.
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- National Cancer Institute
- Remission Alliance
- Charlie Teo Foundation
- Malnati Brain Tumor Institute
Zitieren
APA
Tripathi, S., Najem, H., Dussold, C., Pacheco, S., Du, R., Sooreshjani, M., Hurley, L., Chandler, J. P., Stupp, R., Sonabend, A. M., Horbinski, C. M., Lukas, R. V., Xiu, J., Lopez, G., Nicolaides, T. P., Brown, V., Wadhwani, N. R., Lam, S. K., James, C. D., …, & DeCuypere, M. (2024). Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci177413
Vancouver
Tripathi S, Najem H, Dussold C, Pacheco S, Du R, Sooreshjani M, et al. Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. Journal of Clinical Investigation. 2024. doi:10.1172/jci177413
BibTeX
@article{Tripathi2024,
author = {Tripathi, Shashwat and Najem, Hinda and Dussold, Corey and Pacheco, Sebastian and Du, Ruochen and Sooreshjani, Moloud and Hurley, Lisa and Chandler, James P and Stupp, Roger and Sonabend, Adam M and Horbinski, Craig M and Lukas, Rimas V and Xiu, Joanne and Lopez, Giselle and Nicolaides, Theodore P and Brown, Valerie and Wadhwani, Nitin R and Lam, Sandi K and James, Charles David and Rao, Ganesh and Castro, Maria G and Heimberger, Amy B and DeCuypere, Michael},
title = {Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci177413}
}
EUVIMED